What EdenRoc Sciences does

EdenRoc Sciences, LLC is a privately-held life sciences holding and operating company headquartered in Worcester, Massachusetts (with a secondary office in Cambridge, Massachusetts), founded in 2016 and structured as a Delaware LLC. The company operates a portfolio of approximately ten autonomous subsidiaries spanning clinical-stage pharmaceuticals (Metro International Biotech, developing the world's most comprehensive proprietary NAD booster portfolio for rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance), multiomics tools (Cantata Bio, parent to Dovetail Genomics and Arc Bio, delivering NGS-based products for genome assembly, phasing, chromatin structure, and epigenomics), cell-free DNA sequencing for liquid biopsy (Claret Bioscience), advanced forensic DNA recovery from degraded samples (Astrea Forensics), biologic-based consumer care ingredients derived from a space-survivor Bacillus isolate (Delavie Sciences), US Government and biosecurity partnerships (Liberty Biosecurity), and IP holding entities for short RNA synthesis (UpRNA) and microarray-based pathogen detection (Revere Biosensors).

The company's business model is a holding company structure rather than a traditional product sales operation: EdenRoc founds or acquires subsidiaries based on novel science, often licensed from top universities, and supports each with shared parent-level functions including legal, HR, benefits, accounting, finance, IT, and business planning. Cross-portfolio collaboration is fostered through shared board oversight and parent-level equity grants to employees and advisors. Combined headcount exceeds 100 scientists and staff, supported by over 40 world-class advisors drawn from institutions including Harvard Medical School, MIT, Stanford, and the University of Michigan.

EdenRoc raises capital through private exempt securities offerings filed via SEC Form D under Rule 506(b), with three disclosed offerings between 2022 and 2024 totaling approximately $150 million in aggregate offering capacity. Revenue is not publicly disclosed, and pricing across subsidiary product lines is opaque. The company's leadership is anchored by founder and Chairman Edward Schulak and Vice Chairman Dr. David Sinclair (Harvard Medical School professor and co-Director of the Paul F. Glenn Center for the Biology of Aging Research), with Chairman Emeritus J. Taylor Crandall (Oak Hill Capital founding member) on the board.

Name

EdenRoc Sciences

Legal name

EdenRoc Sciences, LLC

Website

https://edenrocsciences.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

EdenRoc Sciences is a privately-held life sciences holding company that founds and operates autonomous subsidiaries across clinical-stage pharmaceuticals (NAD boosters), NGS-based multiomics tools, forensic DNA recovery, consumer care biologics, and government biosecurity. It serves pharma, research, law enforcement, consumer care, and US Government markets.

Ownership category

akta.pro rank

Product category

Biotechnology Holding Company

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Life sciences portfolio
• Biotechnology holding company
• Clinical stage pharmaceuticals
• Genomic sequencing tools
• Forensic DNA services

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Core offering

EdenRoc Sciences is a life sciences portfolio company that founds, owns, and operates autonomous biotech subsidiaries developing clinical-stage NAD-boosting pharmaceuticals, NGS-based multiomics and genomics tools, cell-free DNA liquid biopsy technologies, forensic DNA recovery services, space-derived biologic consumer care ingredients, RNA therapeutics synthesis platforms, and microarray-based pathogen detection technology. Each subsidiary commercializes its own products and services while EdenRoc provides shared corporate support and cross-subsidiary collaboration.

Product overview

EdenRoc Sciences is a life sciences portfolio/holding company structured as a platform of autonomous subsidiary companies, each focused on different biotechnology markets. The subsidiaries include: Metro International Biotech (clinical-stage pharmaceuticals developing NAD boosters for age-related and mitochondrial diseases); Cantata Bio (multiomics tools company parent to Dovetail Genomics and Arc Bio offering NGS-based products and services); Claret Bioscience (NGS tools for cell-free DNA analysis and liquid biopsy); Astrea Forensics (DNA technology services for degraded forensics samples); Delavie Sciences (consumer care ingredients including Bacillus Lysate); Liberty Biosecurity (US Government partnerships); UpRNA (RNA therapeutics IP); and Revere Biosensors (microarray technology for pathogen detection). The company supports subsidiaries with core business functions while fostering cross-collaboration through shared board oversight and equity grants.

Differentiator

Problem solved

Functional benefit

Products and services

• Metro International Biotech LLC (Metro) Clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD boosters in the world, developing compounds to treat rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance, with potential applications in renal failure, ophthalmic diseases, liver injuries, ischemic injuries, and neuromuscular disorders.
• Cantata Bio Multiomics tools company delivering powerful, novel NGS-based products and services for researchers and clinicians, with integrated metagenomic workflows for microbial detection and quantification and unique long-range sequencing assays for genome assembly, phasing, chromatin structure, and epigenomics.
• Dovetail Genomics NGS-based genomics tools and services providing long-range sequencing assays for industry-leading genome assembly, phasing, chromatin structure, and epigenomics.
• Arc Bio NGS-based products and services focused on enabling researchers and clinicians to solve challenging scientific problems in human disease and agricultural sustainability through microbial detection and quantification.
• Claret Bioscience, LLC Commercial-stage biotechnology company that developed novel technologies for improving NGS-based discovery from cell-free DNA, providing NGS tools and software that exploit novel signals discovered at native termini of DNA fragments, including in single DNA strands, for use in liquid biopsy applications.
• Astrea Forensics, LLC Biotechnology company focused on applying the most advanced DNA technology to forensics casework, offering services to law enforcement and related agencies for recovering, sequencing, and genotyping DNA from degraded forensics samples that fail conventional testing, providing genome-wide solutions for investigative genetic genealogy.
• Delavie Sciences Pioneer in cutting-edge ingredients and products for the consumer care industry; produces Bacillus Lysate, a premiere ingredient derived from a unique biological isolate that survived prolonged exposure on the exterior of the International Space Station, with demonstrated SPF enhancement in sunscreen formulations and antioxidant properties for anti-aging serum applications.
• Liberty Biosecurity Government partnerships subsidiary developing relationships with the US Government and international partners to bring life sciences expertise to unclassified and classified national security challenges while raising non-dilutive funding.
• UpRNA IP holding company with technology enabling researchers working on experimental RNA therapeutics to design and synthesize short RNAs affordably and on demand, removing cost barriers in siRNA therapeutic development.
• Revere Biosensors Biotechnology IP holding company with technology related to novel microarray design, fabrication, and use based on Illumina's bead array technology with enhancements on speed and cost for rapid point-of-care detection and characterization of organisms including pathogens and microbiomes.

Segments5 records

Ideal customer profiles8 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Flagship Pioneering: Biotech venture creation firm that founds and operates multiple platform companies (e.g., Moderna, Generate Biomedicines) from licensed academic science. Closest analog to EdenRoc's holding-company model of founding autonomous subsidiaries around novel university IP and supporting them with centralized resources.
• ARCH Venture Partners: Long-standing biotech creation and investment firm that founds and builds multiple life sciences companies from university-licensed technology. Operates a similar multi-subsidiary model focused on aging, genomics, and therapeutics, mirroring EdenRoc's portfolio construction approach.
• Ginkgo Bioworks: Public platform biotech that develops biological products across multiple end markets through a centralized R&D engine and subsidiary-like programs. Comparable to EdenRoc in operating multiple biotech programs under one umbrella with shared scientific infrastructure.
• Guardant Health: Leading liquid biopsy company commercializing cfDNA-based cancer diagnostics. Most direct commercial-stage peer to Claret Bioscience's cfDNA/liquid biopsy technology and addresses the same translational research and clinical market.
• Natera: Commercial-stage liquid biopsy and cfDNA diagnostics company (Signatera, Vantage) focused on oncology and reproductive health. Directly comparable to Claret Bioscience as a cfDNA platform competing for translational and clinical research customers.
• Pacific Biosciences: Long-read sequencing platform company (HiFi sequencing) competing in genome assembly and structural variant markets that Dovetail Genomics and Cantata Bio also serve. Strong technological overlap for genome assembly, phasing, and epigenomics applications.

Broad incumbents

• 10x Genomics: Leading provider of single-cell and multiomics tools (Chromium, Visium, Xenium) widely used in genomics research. Comparable to Cantata Bio's Dovetail/Arc Bio multiomics offerings as a competitor and as a market-sizing reference for the multiomics tools opportunity.
• Illumina: Dominant NGS platform vendor whose bead array technology underpins Revere Biosensors' microarray IP. As the broader sequencing ecosystem leader, Illumina sets competitive dynamics for Cantata Bio's long-range sequencing and Claret's cfDNA assays.
• NanoString Technologies: Provider of spatial biology and multiomics research tools (GeoMx, CosMx, nCounter) serving the same translational and clinical research customer base as Cantata Bio. Comparable as a broader multiomics platform competitor.

Emerging players

• Insitro: Machine learning-driven drug discovery company building a platform of therapeutic programs from biological data. Comparable to EdenRoc's model of operating multiple programs under shared infrastructure, with a sharper focus on AI-enabled small-molecule discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries10 records

Funding overview

Funding rounds12 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EdenRoc Sciences